Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539318 | 1.00 | NOTUM (1.00) | NOTUMKMT2AMAPTTAAR1MEN1 | |
| SCHEMBL249471 | 0.90 | NOTUM (0.81) | NOTUMKMT2AMAPTTAAR1MEN1 | |
| SCHEMBL7227468 | 0.89 | NOTUM (0.80) | NOTUMKMT2AMAPTTAAR1MEN1 | |
| SCHEMBL1197829 | 0.86 | NOTUM (1.00) | NOTUMKMT2AMAPTTAAR1MEN1 | |
| SCHEMBL27901981 | 0.84 | NOTUM (0.72) | NOTUMKMT2AMAPTTAAR1MEN1 | |
| SCHEMBL322928 | 0.82 | NOTUM (0.70) | NOTUMKMT2AMAPTTAAR1MEN1 | |
| SCHEMBL4290743 | 0.82 | NOTUM (0.70) | NOTUMKMT2AMAPTTAAR1MEN1 | |
| SCHEMBL16281586 | 0.82 | NOTUM (0.70) | NOTUMKMT2AMAPTTAAR1MEN1 | |
| SCHEMBL20752768 | 0.82 | NOTUM (0.67) | NOTUMKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL18689693 | 0.81 | NOTUM (0.68) | NOTUMKMT2AMAPTTAAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | claimed |
| WO-2014039769-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-13 | — | — | WO | claimed |
| EP-0245960-B1 | PROCESS FOR PREPARING N-ACYLTETRAHYDROISOQUINOLINE | Takasago Perfumery Co., Ltd. (JP) | 1992-07-29 | — | — | EP | claimed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023076219-A2 | ANTAGONISTS OF GPR39 PROTEIN | VASOCARDEA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| EP-3444238-B1 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | SATO PHARMA (JP) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021222858-A1 | ANTAGONISTS OF GPR39 PROTEIN | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-0076559-A1 | Antiallergic imidosulfamides | SMITHKLINE BECKMAN CORPORATION (US) | 1983-04-13 | — | — | EP | disclosed |
| EP-0074741-A1 | Method of producing alpha2 antagonism | SMITHKLINE BECKMAN CORPORATION (US) | 1983-03-23 | — | — | EP | disclosed |
| US-4352809-A | THIADIAZOLO- AND OXADIAZOLOTETRAHYDROISOQUINOLINES, ANTIDEPRESSANTS | SMITHKLINE CORPORATION (US) | 1982-10-05 | — | — | US | disclosed |
| US-4350698-A | ASTHMA | SMITHKLINE CORPORATION (US) | 1982-09-21 | — | — | US | disclosed |
| US-4315935-A | INHIBITING THE SYMPTOMS OF ASTHMA | SMITHKLINE CORPORATION (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0038177-A1 | Antiallergic imidodisulfamides, pharmaceutical compositions containing them and process for their preparation | SMITHKLINE BECKMAN CORPORATION (US) | 1981-10-21 | — | — | EP | disclosed |
| US-4258049-A | Inhibiting phenylethanolamine N-methyltransferase with thiadiazolo and oxadiazolotetrahydroisoquinolines | SMITHKLINE CORPORATION (US) | 1981-03-24 | — | — | US | disclosed |
| EP-0023761-A1 | Tetrahydroisoquinoline derivatives, process for preparing them and compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1981-02-11 | — | — | EP | disclosed |
| US-4228170-A | INHIBITOR OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE | SMITHKLINE CORPORATION (US) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | NOTUM 4102/4885KMT2A 968/4885MAPT 458/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | NOTUM 2896/4885KMT2A 4441/4885MAPT 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.